

EDIT IMPLEMENTATION SCHEDULE

Clinical edits are designed to enhance patient care and optimize the use of program funds through the therapeutically prudent use of pharmaceuticals. Point-of-service pharmacy claims will be routed through an automated computer system to apply edits specifically designed to assure effective drug utilization. The edits are based on evidence-based clinical criteria and available nationally recognized peer-reviewed information. Through the clinical edit process, therapy will automatically and transparently be approved for those patients who meet any of the system approval criteria. For those participants who do not meet the system approval criteria, therapy will require a call to the MO HealthNet Drug Prior Authorization hotline at **(800) 392-8030** to initiate a review and potentially authorize claims. MO HealthNet will use the clinical edit program software to implement a state specific Preferred Drug List (PDL).

| Scheduled Therapeutic Class/Drug Product Edits | Effective Date |
|--|-----------------------|
| C5 Complement Inhibitors Clinical Edit (NEW) | 08/04/2022 |
| Fabry Disease Clinical Edit (Annual) | 08/04/2022 |
| Givlaari Clinical Edit (Annual) | 08/04/2022 |
| Imcivree Clinical Edit (Annual) | 08/04/2022 |
| Isturisa Clinical Edit (Annual) | 08/04/2022 |
| Nulibry Clinical Edit (Annual) | 08/04/2022 |
| Oxervate Clinical Edit (Annual) | 08/04/2022 |
| Oxlumo Clinical Edit (Annual) | 08/04/2022 |
| Scenesse Clinical Edit (NEW) | 08/04/2022 |
| Systemic Antifungals Clinical Edit (Annual) | 08/04/2022 |
| Tavneos Clinical Edit (NEW) | 08/04/2022 |
| Voxzogo Clinical Edit (NEW) | 08/04/2022 |
| Zokinvy Clinical Edit (Annual) | 08/04/2022 |
| Acne & Rosacea – Select Topical Agents Step Therapy Edit (Annual) | 07/28/2022 |
| Sickle Cell Disease Clinical Edit (Annual) | 07/28/2022 |
| Zulresso Clinical Edit (Annual) | 07/28/2022 |
| Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit (Annual) | 07/21/2022 |
| Megestrol Acetate Clinical Edit (Annual) | 07/21/2022 |
| Spravato Clinical Edit (Annual) | 07/21/2022 |
| Actinic Keratosis Agents, Topical PDL Edit (Annual) | 07/07/2022 |
| Androgenic Agents PDL Edit (Annual) | 07/07/2022 |
| Antibiotics, Inhaled PDL Edit PDL Edit (Annual) | 07/07/2022 |
| Anticholinergics, LABA Combinations PDL Edit (Annual) | 07/07/2022 |
| Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors PDL Edit (Annual) | 07/07/2022 |
| Anticholinergics, Long Acting Inhaled PDL Edit (Annual) | 07/07/2022 |
| Anticholinergics, Short Acting and Combinations Inhaled PDL Edit (Annual) | 07/07/2022 |
| Antifungals, Oral PDL Edit (Annual) | 07/07/2022 |
| Antifungals, Topical PDL Edit (Annual) | 07/07/2022 |
| Antihistamines & Antihistamines/Decongestant Combinations, 2nd Generation PDL Edit (Annual) | 07/07/2022 |
| Antihistamines, Intranasal PDL Edit (Annual) | 07/07/2022 |
| Antihistamines, Ophthalmic PDL Edit (Annual) | 07/07/2022 |
| Antiparasitics, Topical PDL Edit (Annual) | 07/07/2022 |
| Antivirals, Herpes Oral PDL Edit (Annual) | 07/07/2022 |
| Antivirals, Topical PDL Edit (Annual) | 07/07/2022 |
| Atopic Dermatitis Agents, Immunomodulators PDL Edit (Annual) | 07/07/2022 |
| Benzoyl Peroxide/Antibiotic Combinations PDL Edit (Annual) | 07/07/2022 |
| Beta Adrenergic Agents, Long Acting PDL Edit (Annual) | 07/07/2022 |
| Beta Adrenergic Agents, Nebulized PDL Edit (Annual) | 07/07/2022 |
| Beta Adrenergic Agents, Short Acting PDL Edit (Annual) | 07/07/2022 |
| Corticosteroids and Rhinitis Agents, Intranasal PDL Edit (Annual) | 07/07/2022 |

| Scheduled Therapeutic Class/Drug Product Edits | Effective Date |
|--|----------------|
| Corticosteroids, Ophthalmic Soft PDL Edit (Annual) | 07/07/2022 |
| Corticosteroids, Oral Inhaled PDL Edit (Annual) | 07/07/2022 |
| Corticosteroids, Topical PDL Edit (Annual) | 07/07/2022 |
| Cough/Cold Preparations PDL Edit (Annual) | 07/07/2022 |
| Epinephrine Agents, Self-Injectable PDL Edit (Annual) | 07/07/2022 |
| Fluoroquinolones, Ophthalmic PDL Edit (Annual) | 07/07/2022 |
| Fluoroquinolones, Otic PDL Edit (Annual) | 07/07/2022 |
| Glaucoma Agents PDL Edit (Annual) | 07/07/2022 |
| Hepatitis C Agents PDL Edit (Annual) | 07/07/2022 |
| Leukotriene Receptor Modifiers PDL Edit (Annual) | 07/07/2022 |
| Mast Cell Stabilizers, Ophthalmic PDL Edit (Annual) | 07/07/2022 |
| NSAIDs, Ophthalmic PDL Edit (Annual) | 07/07/2022 |
| Pancreatic Enzymes PDL Edit (Annual) | 07/07/2022 |
| Psoriasis Agents, Oral PDL Edit (Annual) | 07/07/2022 |
| Psoriasis Agents, Topical PDL Edit (Annual) | 07/07/2022 |
| Respiratory Monoclonal Antibodies (RMA) PDL Edit (Annual) | 07/07/2022 |
| Retinoids, Topical PDL Edit (Annual) | 07/07/2022 |
| Ulcerative Colitis Agents, Oral PDL Edit (Annual) | 07/07/2022 |
| Ulcerative Colitis Agents, Rectal PDL Edit (Annual) | 07/07/2022 |
| 15 Day Supply – Oral Oncology Fiscal Edit (Annual) | 05/19/2022 |
| 15 Day Supply Fiscal Edit (Annual) | 05/19/2022 |
| Biosimilar vs Reference Products Fiscal Edit (Annual) | 05/19/2022 |
| Diabetic Supply Quantity Limit Fiscal Edit (Annual) | 05/12/2022 |
| Extended Supply Fiscal Edit (Annual) | 05/12/2022 |
| High Cost Medications Fiscal Edit (Annual) | 05/12/2022 |
| Acetaminophen Cumulative Dose Clinical Edit (Annual) | 05/05/2022 |
| Non-Oral Contraceptives Fiscal Edit (Annual) | 05/05/2022 |
| Out-of-State, Non-Bordering Pharmacies Fiscal Edit (Annual) | 05/05/2022 |
| Selzentry Clinical Edit (Annual) | 05/05/2022 |
| BiDil Clinical Edit (Annual) | 04/28/2022 |
| Corlanor Clinical Edit (Annual) | 04/28/2022 |
| Kerendia Clinical Edit (NEW) | 04/28/2022 |
| Benzodiazepines (Select Oral) Clinical Edit (Annual) | 04/28/2022 |
| Butalbital Combinations Excessive Therapy Edit (Annual) | 04/21/2022 |
| Butalbital Combinations without Codeine Clinical Edit (Annual) | 04/21/2022 |
| Empaveli Clinical Edit (NEW) | 04/21/2022 |
| Pompe Disease Clinical Edit (NEW) | 04/21/2022 |
| Spinal Muscular Atrophy (SMA) Clinical Edit (Annual) | 04/21/2022 |
| Antipsychotics – 1 st Generation (Typical) Clinical Edit (Annual) | 04/07/2022 |
| Antipsychotics – 2 nd Generation (Atypical) Clinical Edit and Reference List (Annual) | 04/07/2022 |
| High Risk Therapies Clinical Edit (Annual) | 04/07/2022 |
| Morphine Milligram Equivalent Accumulation Clinical Edit (Annual) | 04/07/2022 |
| Opioids – Short-Acting Clinical Edit (Annual) | 04/07/2022 |
| Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit (Annual) | 04/07/2022 |
| Alzheimer’s Agents, AChEIs and NMDA Receptor Antagonists PDL Edit (Annual) | 04/07/2022 |
| Antiandrogenic Agents PDL Edit (Annual) | 04/07/2022 |
| Anticonvulsants, Dravet Syndrome PDL Edit (Annual) | 04/07/2022 |
| Antiemetics, 5-HT3 and NK1 Injectables PDL Edit (Annual) | 04/07/2022 |
| Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables PDL Edit (Annual) | 04/07/2022 |
| Antiemetics, THC Derivatives PDL Edit (Annual) | 04/07/2022 |
| Anti-Migraine, Alternative Oral Agents PDL Edit (Annual) | 04/07/2022 |
| Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit (Annual) | 04/07/2022 |
| Anti-Parkinsonism, MAO-B Inhibitors PDL Edit (Annual) | 04/07/2022 |
| Anti-Parkinsonism, Non-Ergot Dopamine Agonists PDL Edit (Annual) | 04/07/2022 |

| Scheduled Therapeutic Class/Drug Product Edits | Effective Date |
|--|----------------|
| Antiretroviral Therapy (ART) PDL Edit (NEW) | 04/07/2022 |
| Bile Salt Agents PDL Edit (Annual) | 04/07/2022 |
| Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit (Annual) | 04/07/2022 |
| Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit (Annual) | 04/07/2022 |
| Fibromyalgia Agents PDL Edit (Annual) | 04/07/2022 |
| GI Motility Agents, Chronic PDL Edit (Annual) | 04/07/2022 |
| Glucagon Agents PDL Edit (Annual) | 04/07/2022 |
| Hereditary Angioedema Agents PDL Edit (Annual) | 04/07/2022 |
| Homozygous Familial Hypercholesterolemia (HoFH) PDL Edit (Annual) | 04/07/2022 |
| Neuropathic Pain Agents PDL Edit (Annual) | 04/07/2022 |
| NSAIDs PDL Edit (Annual) | 04/07/2022 |
| Opioid Dependence Agents PDL Edit (Annual) | 04/07/2022 |
| Opioid Emergency Reversal Agents PDL Edit (Annual) | 04/07/2022 |
| Opioids, Long Acting PDL Edit (Annual) | 04/07/2022 |
| Sedative Hypnotics PDL Edit (Annual) | 04/07/2022 |
| Skeletal Muscle Relaxants PDL Edit (Annual) | 04/07/2022 |
| Somatostatin Analogs PDL Edit (Annual) | 04/07/2022 |
| Tramadol-Like Agents PDL Edit (Annual) | 04/07/2022 |
| Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit (Annual) | 04/07/2022 |
| Equetro Clinical Edit (Annual) | 02/17/2022 |
| Nuedexta Clinical Edit (Annual) | 02/17/2022 |
| Ranexa Clinical Edit (Annual) | 02/17/2022 |
| Botulinum Toxin Clinical Edit (Annual) | 02/10/2022 |
| Emsam Clinical Edit (Annual) | 02/10/2022 |
| Lambert-Eaton Myasthenic Syndrome (LEMS) Clinical Edit (Annual) | 02/10/2022 |
| Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit (Annual) | 02/10/2022 |
| Palforzia Clinical Edit (NEW) | 02/10/2022 |
| Continuous Glucose Monitors (CGMs) Clinical Edit (Annual) | 02/03/2022 |
| Insulin Pumps – Tubeless Clinical Edit (Annual) | 02/03/2022 |
| Narcolepsy Inhibitors Clinical Edit (Annual) | 02/03/2022 |
| Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit (Annual) | 02/03/2022 |
| Xcopri Clinical Edit (Annual) | 02/03/2022 |
| Psychotropic Medications Polypharmacy Clinical Edit (Annual) | 02/01/2022 |
| Aduhelm Clinical Edit (NEW) | 01/27/2022 |
| Immunoglobulins (IVIG and SCIG) Clinical Edit (Annual) | 01/27/2022 |
| Oxandrin Clinical Edit (Annual) | 01/27/2022 |
| Selective Serotonin Reuptake Inhibitors (SSRI) Step Therapy Edit (Annual) | 01/20/2022 |
| Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Clinical Edit (Annual) | 01/20/2022 |
| ACE-Inhibitors and ACE-Inhibitors/Diuretic Combinations PDL Edit (Annual) | 01/06/2022 |
| ACE-Inhibitors/CCB Combinations PDL Edit (Annual) | 01/06/2022 |
| ADHD, Amphetamines, Long-Acting PDL Edit (Annual) | 01/06/2022 |
| ADHD, Amphetamines, Short-Acting PDL Edit (Annual) | 01/06/2022 |
| ADHD, Methylphenidate, Long-Acting PDL Edit (Annual) | 01/06/2022 |
| ADHD, Methylphenidate, Short-Acting PDL Edit (Annual) | 01/06/2022 |
| ADHD, Non-Stimulants PDL Edit (Annual) | 01/06/2022 |
| Anticoagulants PDL Edit (Annual) | 01/06/2022 |
| Anticonvulsants, Rescue Agents PDL Edit (Annual) | 01/06/2022 |
| Antiplatelets PDL Edit (Annual) | 01/06/2022 |
| ARBs and ARBs/Diuretic Combinations PDL Edit (Annual) | 01/06/2022 |
| ARBs/CCB Combinations PDL Edit (Annual) | 01/06/2022 |
| Beta Blockers and Beta Blockers/Diuretic Combinations PDL Edit (Annual) | 01/06/2022 |
| CCBs, Dihydropyridines PDL Edit (Annual) | 01/06/2022 |
| CCBs, Non-Dihydropyridines PDL Edit (Annual) | 01/06/2022 |
| Direct Renin Inhibitors and Combinations PDL Edit (Annual) | 01/06/2022 |

| Scheduled Therapeutic Class/Drug Product Edits | Effective Date |
|---|----------------|
| Dry Eye Disease PDL Edit (Annual) | 01/06/2022 |
| Niacin Derivatives PDL Edit (Annual) | 01/06/2022 |
| PAH, Endothelin Receptor Antagonists (ETRA)s PDL Edit (Annual) | 01/06/2022 |
| PAH, PDE5-Inhibitors and SGC Stimulators PDL Edit (Annual) | 01/06/2022 |
| PAH, Prostacyclins, Inhaled PDL Edit (Annual) | 01/06/2022 |
| PAH, Prostacyclins, Injectable PDL Edit (Annual) | 01/06/2022 |
| PAH, Prostacyclins, Oral PDL Edit (Annual) | 01/06/2022 |
| Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Binders PDL Edit (Annual) | 01/06/2022 |
| Proton Pump Inhibitors PDL Edit (Annual) | 01/06/2022 |
| Statins (HMG Co-A Reductase Inhibitors) & Combinations PDL Edit (Annual) | 01/06/2022 |
| Sympatholytic Agents PDL Edit (Annual) | 01/06/2022 |
| Triglyceride Lowering Agents PDL Edit (Annual) | 01/06/2022 |
| CAR-T Cell Therapy Clinical Edit (Annual) | 11/18/2021 |
| Gamifant Clinical Edit (Annual) | 11/18/2021 |
| Imcivree Clinical Edit (NEW) | 11/18/2021 |
| Koselugo Clinical Edit (Annual) | 11/18/2021 |
| Luxturna Clinical Edit (Annual) | 11/18/2021 |
| Nulibry Clinical Edit (NEW) | 11/18/2021 |
| Oxervate Clinical Edit (Annual) | 11/18/2021 |
| Palynziq Clinical Edit (Annual) | 11/18/2021 |
| Reblozyl Clinical Edit (Annual) | 11/18/2021 |
| Tepezza Clinical Edit (Annual) | 11/18/2021 |
| Zokinvy Clinical Edit (NEW) | 11/18/2021 |
| Duchenne Muscular Dystrophy (DMD) Clinical Edit (Annual) | 11/18/2021 |
| Ampyra Clinical Edit (Annual) | 11/11/2021 |
| Elagolix Clinical Edit (Annual) | 11/11/2021 |
| Iron – Injectable Step Therapy Edit (Annual) | 11/11/2021 |
| HBV Nucleotide Analog Reverse Transcriptase Inhibitors Fiscal Edit (NEW) | 11/04/2021 |
| Parathyroid Hormone & Bone Resorption Suppression Related Agents Clinical Edit (Annual) | 11/04/2021 |
| Zometa Clinical Edit (Annual) | 11/04/2021 |
| Crysvita Clinical Edit (Annual) | 10/28/2021 |
| Oxazolidinone Fiscal Edit (NEW) | 10/28/2021 |
| Tolvaptan Clinical Edit (Annual) | 10/28/2021 |
| Entresto Clinical Edit (Annual) | 10/21/2021 |
| Extended Supply Fiscal Edit (NEW) | 10/21/2021 |
| Verquvo Clinical Edit (NEW) | 10/21/2021 |
| Synagis Clinical Edit (Annual) | 10/07/2021 |
| Alpha-Glucosidase Inhibitors PDL Edit (Annual) | 10/07/2021 |
| Amylin Analogs PDL Edit (Annual) | 10/07/2021 |
| Antibiotics, GI Oral PDL Edit (Annual) | 10/07/2021 |
| Antibiotics, Mupirocin Topical PDL Edit (NEW) | 10/07/2021 |
| Antibiotics, Vaginal PDL Edit (Annual) | 10/07/2021 |
| Antihyperuricemic Agents PDL Edit (Annual) | 10/07/2021 |
| Benign Prostatic Hyperplasia Agents PDL Edit (Annual) | 10/07/2021 |
| Biguanides and Combinations PDL Edit (Annual) | 10/07/2021 |
| Bile Salt Agents PDL Edit (Annual) | 10/07/2021 |
| Bone Ossification Agents PDL Edit (Annual) | 10/07/2021 |
| Cephalosporin Agents PDL Edit (Annual) | 10/07/2021 |
| Colony Stimulating Factors PDL Edit (Annual) | 10/07/2021 |
| Cyropyrin-Associated Periodic Syndrome (CAPS) Agents PDL Edit (Annual) | 10/07/2021 |
| DPP-IV Inhibitors and Combinations PDL Edit (Annual) | 10/07/2021 |
| Electrolyte Depleting Agents, Phosphate Lowering PDL Edit (Annual) | 10/07/2021 |
| Electrolyte Depleting Agents, Potassium Lowering PDL Edit (Annual) | 10/07/2021 |

| Scheduled Therapeutic Class/Drug Product Edits | Effective Date |
|--|----------------|
| Erythropoiesis Stimulating Agents PDL Edit (Annual) | 10/07/2021 |
| Fluoroquinolone Agents, Oral PDL Edit (Annual) | 10/07/2021 |
| GLP-1 Receptor Agonists and Combinations PDL Edit (Annual) | 10/07/2021 |
| Growth Hormone Agents, Somatropin PDL Edit (Annual) | 10/07/2021 |
| Growth Hormone and Growth Hormone Releasing Factors, Select Agents PDL Edit (Annual) | 10/07/2021 |
| Insulin, Long Acting PDL Edit (Annual) | 10/07/2021 |
| Insulin, Mixed PDL Edit (Annual) | 10/07/2021 |
| Insulin, Non-Analogs PDL Edit (Annual) | 10/07/2021 |
| Insulin, Rapid Acting PDL Edit (Annual) | 10/07/2021 |
| LHRH/GnRH Agents, Non-Oral PDL Edit (NEW) | 10/07/2021 |
| Macrolides PDL Edit (Annual) | 10/07/2021 |
| Meglitinides PDL Edit (Annual) | 10/07/2021 |
| Methotrexate Agents PDL Edit (Annual) | 10/07/2021 |
| Multiple Sclerosis Agents, Injectable PDL Edit (Annual) | 10/07/2021 |
| Multiple Sclerosis Agents, Oral PDL Edit (Annual) | 10/07/2021 |
| Penicillin Agents PDL Edit (Annual) | 10/07/2021 |
| SGLT2 Inhibitors and Combinations PDL Edit (Annual) | 10/07/2021 |
| Sulfonylureas, Second Generation PDL Edit (Annual) | 10/07/2021 |
| Targeted Immune Modulators, IL17 Antibody/IL17 Receptor Antagonists PDL Edit (Annual) | 10/07/2021 |
| Targeted Immune Modulators, IL23 Inhibitors and IL23/IL12 Inhibitors PDL Edit (Annual) | 10/07/2021 |
| Targeted Immune Modulators, IL6 Receptor Inhibitors PDL Edit (Annual) | 10/07/2021 |
| Targeted Immune Modulators, JAK Inhibitors PDL Edit (Annual) | 10/07/2021 |
| Targeted Immune Modulators, Select Agents PDL Edit (Annual) | 10/07/2021 |
| Targeted Immune Modulators, TNF Inhibitors PDL Edit (Annual) | 10/07/2021 |
| Tetracycline Agents PDL Edit (Annual) | 10/07/2021 |
| Thiazolidinediones and Combinations PDL Edit (Annual) | 10/07/2021 |
| Thrombocytopenia Agents PDL Edit (Annual) | 10/07/2021 |
| Urinary Tract Antispasmodics PDL Edit (Annual) | 10/07/2021 |